Grifols has launched FESILTY™ (fibrinogen, human-chmt) in the United States, marking the commercial availability of a plasma-derived fibrinogen concentrate indicated for acute bleeding episodes in patients with congenital fibrinogen deficiency (CFD), including hypo- and afibrinogenemia. The FDA granted approval in December 2025, and the Barcelona-based plasma therapeutics company — listed on both the Madrid Stock Exchange (GRF, GRF.P) and NASDAQ (GRFS) — confirmed U.S. market entry on June 15, 2026.
Fibrinogen is a critical clotting protein synthesized in the liver; patients with CFD produce insufficient or structurally abnormal fibrinogen, leaving them unable to form stable clots during bleeding events. FESILTY is a human-derived, plasma-fractionated finished formulation designed to restore functional fibrinogen levels in both pediatric and adult populations. The product is not indicated for dysfibrinogenemia, a structurally distinct disorder in which fibrinogen is present but dysfunctional — a regulatory boundary that operators and specialty pharmacists will need to communicate clearly at point of dispensing.
Congenital fibrinogen deficiency is classified as an ultra-rare disorder, with global prevalence estimates in the low single-digit per-million range. While that positions FESILTY outside mainstream nutraceutical or functional food channels, its approval is directionally relevant to the broader plasma-derived ingredient and specialty nutrition sector. Plasma-derived proteins — including immunoglobulins, albumin, and clotting factors — increasingly inform ingredient innovation in medical nutrition and condition-specific functional formulations, particularly as manufacturers look to bioavailability-optimized protein fractions for clinical and near-clinical applications. For coverage of how plasma and collagen-derived proteins are moving into functional finished goods, see our earlier reporting on bioactive peptides in clinical nutrition and specialty protein ingredient sourcing.
Grifols is one of the world's largest plasma collectors and fractionators, operating donor centers across the U.S. and Europe. The launch of FESILTY reinforces the company's rare-disease biologics pipeline while also signaling continued investment in plasma supply chain infrastructure — a dynamic that has downstream implications for ingredient suppliers and co-manufacturing partners in the broader functional and medical nutrition space. The rare-disease biologics market has attracted sustained capital in recent years, with payers and health systems prioritizing products that address high-unmet-need indications with limited therapeutic alternatives.
For formulators and brand operators in adjacent specialty nutrition categories, the FESILTY launch underscores the regulatory rigor applied to plasma-derived ingredients — a standard that increasingly sets the evidentiary bar for structure-function claims across functional food and supplement categories as FDA scrutiny of biologically active protein ingredients continues to intensify.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.